- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Vaccination
- Arexvy
- Adults (18-64 years)
- Fragile population
- People at high risk of STIs
- Immunocompromised host
- PrEP users
- People living with HIV
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- Respiratory syncytial virus
- Bordetella pertussis
- Blood sample
- Nasopharyngeal swab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Non pharmacological intervention
- Lung ultrasound
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- Respiratory syncytial virus
- Blood sample
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Children (1-11 years)
- Adolescents (12-17 years)
- Community
- SARS-CoV-2
- Influenza-like illness/Acute respiratory infection
- Pregnant women
- Community
- Arbovirus
- Vector-borne disease
- Zika virus
- Venezuelan equine encephalitis virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Pregabalin
- Adults (18-64 years)
- General population
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- Respiratory syncytial virus
- Influenza-like illness/Acute respiratory infection
- General population
- Infants (<1 year)
- Community
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Corticosteroid
- Methylprednisolone
- General population
- Infants (<1 year)
- Hospital
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Immunoadsorption
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Monoclonal antibodies
- AZD3152/Sipavibart
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Hydroxy gas
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab